文献速递糖尿病

新发1型糖尿病青年中持续葡萄糖监测指标与刺激后C肽指标的相关性

Associations of CGM Metrics With Stimulated C-Peptide Measures in Youth With Recent-Onset Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2025-01-01

研究在103名新诊断1型糖尿病儿童中比较持续葡萄糖监测(CGM)指标与混合餐耐量试验来源的C肽指标至诊断后52周,发现CGM指标与C肽曲线下面积中度相关,但相关强度及预测峰值C肽≥0.2 pmol/mL的敏感度与特异度不足以替代临床试验中的C肽检测。

要点

  • 在103名新发1型糖尿病儿童中,CGM指标与刺激后C肽曲线下面积呈中度相关。
  • 52周时,目标范围内时间(70-180 mg/dL)与C肽的Spearman相关系数为0.45。
  • 预测峰值C肽≥0.2 pmol/mL时,联合三项CGM指标的敏感度为68.4%、特异度为75%。

核心结论

  • CGM指标与刺激后C肽指标相关,但相关强度及CGM衍生指标的敏感度和特异度不足以在临床试验中替代C肽检测。

研究设计与样本

  • 研究比较了103名新诊断1型糖尿病儿童在诊断后至52周多个时间点的CGM指标与混合餐耐量试验来源的C肽指标。

主要发现

  • 52周时,CGM指标与C肽曲线下面积呈中度相关。
  • 与C肽曲线下面积相关性最高的CGM指标为:目标范围内时间(70-180 mg/dL)的Spearman相关系数0.45,低于70 mg/dL时间的相关系数-0.33,葡萄糖变异系数的相关系数-0.58。
  • 使用上述三项CGM指标的多元模型相关性略高,为0.63。
  • 预测峰值C肽浓度≥0.2 pmol/mL时,该联合模型的敏感度为68.4%,特异度为75%。

关键数值与推荐

  • 目标范围内时间(70-180 mg/dL)与C肽曲线下面积的Spearman相关系数为0.45。
  • 低于70 mg/dL时间与C肽曲线下面积的Spearman相关系数为-0.33。
  • 葡萄糖变异系数与C肽曲线下面积的Spearman相关系数为-0.58。
  • 联合三项CGM指标的多元模型与C肽曲线下面积的相关系数为0.63。
  • 预测峰值C肽≥0.2 pmol/mL时,联合模型的敏感度为68.4%,特异度为75%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • CGM指标与C肽指标的相关强度以及CGM衍生指标的敏感度和特异度不够高,不足以在临床试验中替代C肽检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Continuous glucose monitoring (CGM) measures could be a surrogate for stimulated C-peptide outcomes in type 1 diabetes trials. RESEARCH DESIGN AND METHODS: CGM and mixed-meal tolerance test-derived C-peptide measures at time points out to 52 weeks after diagnosis were compared in 103 children. RESULTS: At 52 weeks, CGM metrics moderately correlated with C-peptide area under the curve. The highest Spearman correlations were for time-in-range 70-180 mg/dL, time <70 mg/dL, and glucose coefficient of variation (0.45, -0.33, and -0.58, respectively; the multivariate model using these three metrics had a slightly higher correlation of 0.63). For predicting peak C-peptide concentrations ≥0.2 pmol/mL, this combination had a sensitivity of 68.4% and specificity of 75%. CONCLUSIONS: CGM measures correlated with stimulated C-peptide measures; however, the strength of the correlations and sensitivity and specificity of CGM-derived measures were not great enough to replace C-peptide measures in clinical trials.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Neyman A, DiMeglio LA, Bauza C, et al. Associations of CGM Metrics With Stimulated C-Peptide Measures in Youth With Recent-Onset Type 1 Diabetes. Diabetes Care. 2025. PMID: 40465453. doi:10.2337/dc25-0291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。